Nobel Laureate Headlines Global Discussion in Cell & Gene Therapy in London

PISCATAWAY, N.J., Sept. 8, 2025 /PRNewswire/ — Cell and gene therapies (CGT) are advancing rapidly and are reshaping the future of medicine. From CRISPR-based genome editing to new applications of in vivo and ex vivo cell therapies, scientific breakthroughs are increasingly moving from the laboratory into clinical practice. At the same time, global investment and innovation in the field are accelerating, positioning CGT as one of the fastest-growing areas in life sciences.

One of the greatest challenges for the industry lies in translating these advances into lasting patient benefits and sustainable clinical impact. To address the opportunities and challenges of this evolving landscape, the GenScript Biotech Global Forum London 2025 will take place on November 20th, 2025, in London, United Kingdom, alongside the Jefferies London Healthcare Conference. Under the theme “THE NEXT ERA OF CGT IS HERE,” the forum will bring together a Nobel Laureate, industry pioneers, and investors to explore how today’s innovations can evolve into tomorrow’s standards of care.

RSVP: http://bit.ly/467jaet
(Register with code GSGM1 to claim a complimentary ticket — limited to the first 20 registrants)

Meet Keynote Speakers

The forum is honored to feature an extraordinary assembly of pioneering minds, headlined by Nobel Laureate Dr. Craig Mello, acclaimed for his co-discovery of RNA interference which revolutionized genetic research and paved the way for an entire class of RNA-based therapeutics. He will explore how foundational science can transition into real clinical impact.

Dr. Carl June, Richard W. Vague Professor in Immunotherapy, Director of the Center for Cellular Immunotherapies, University of Pennsylvania. His groundbreaking work led to the first FDA-approved CAR-T cell therapy, reshaping modern cancer treatment. Dr. June will present the latest advances and future directions in cellular immunotherapies.

Dr. Miguel Forte , current President of the International Society for Cell & Gene Therapy (ISCT). With deep expertise in clinical translation and regulatory strategy, he will offer a global perspective on clinical translation, manufacturing (CMC) challenges, and regulatory pathways that will shape the scalability and accessibility of CGT.

The Afternoon and Evening Program will Feature:

  • 3 keynote speeches from renowned leading experts in CGT industry
  • 3 in-depth panel discussions tackling core industry challenges
  • 1 fireside chat on future innovation opportunities in CGT.
  • 20 distinguished speakers sharing insights across the scientific, clinical, and investment spectrum
  • 1 reception fostering meaningful dialogue and connections

Focused Discussions on Industry Priorities

The forum’s agenda will address the topics that matter most to the CGT ecosystem, including:

  • Navigating the Future of Cell Therapy: Evaluating Varied Pathways in Cell Therapy Innovation for Comprehensive Sector Insights
  • Latest Progress and Future Outlook in Gene Therapy and mRNA
  • From Lab to Patient: Overcoming CMC Barriers in Cell and Gene Therapy Manufacturing
  • Innovation and Investment for CGT

In today’s rapidly evolving CGT industry, opportunities and challenges exist side by side. The GenScript Biotech Global Forum London 2025 offers a top-tier platform to directly engage with world-leading scientists, industry pioneers, and investors.

Registration is Now Open

Date: Thursday, November 20, 2025
Location: 116 Pall Mall, London, UK

RSVP: http://bit.ly/467jaet
(Register with code GSGM1 to claim a complimentary ticket — limited to the first 20 registrants)

 

View original content:https://www.prnewswire.com/news-releases/nobel-laureate-headlines-global-discussion-in-cell–gene-therapy-in-london-302549124.html

SOURCE GenScript Biotech Corporation

Staff

Recent Posts

GaraHerb Supplement Facts, Ingredient Label Details, and Product Disclosures: A 2026 Informational Overview of Male Enhancement Supplement Options

Label-verified GaraHerb ingredient disclosures, manufacturing and policy transparency details, and what consumers searching for GaraHerb…

22 hours ago

Cannabix Technologies announces Non-Brokered LIFE Private Placement

  NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES…

22 hours ago

LuminEye Nano-Drops Product Information Updated as Consumer Interest in Eye Health Supplement Options and Vision Support Alternatives Grows in 2026

An informational overview examining category context, publicly available product disclosures, and what consumers often consider…

22 hours ago

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”)…

22 hours ago

Laughland Teeth Whitening Kit: Ingredients, Disclosures, and What Consumers Are Researching in 2026

A 2026 informational overview of the Laughland whitening kit covering publicly available ingredient disclosures, product…

22 hours ago

The UA Sprinkler Fitters Local 669 JATC – Notice of Privacy Incident

Landover, Maryland, February 6, 2026- The UA Sprinkler Fitters Local 669 Joint Apprenticeship and Training…

1 day ago